BRINZOLAMIDE

Search structure
Trade Names:
Synonyms:
Status: Approved (1998)
Entry Type: Small molecule
Molecule Category: Parent
ATC: S01EC04
UNII: 9451Z89515

Structure
InChI Key HCRKCZRJWPKOAR-JTQLQIEISA-N
Smile CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21
InChI
InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C12H21N3O5S3
Molecular Weight 383.52
AlogP 0.09
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 118.8
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 23.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Carbonic anhydrase II inhibitor DailyMed
Primary Target
carbonic anhydrase 7
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Lyase
- 3-45 0 0-45 -
Enzyme
- 3-45 0 0-45 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Ocular Hypertension 4 D009798 ClinicalTrials
Central Serous Chorioretinopathy 2 D056833 ClinicalTrials

Related Entries

MCS

Scaffolds

Mixture

Side Effects from Label

Side effects Relative Frequency (%) Labels
General disorders and administration site conditions Discomfort 11.1
Gastrointestinal disorders Dysgeusia 6.0
Gastrointestinal disorders Dysgeusia 5.5
Eye disorders Vision blurred 5.4
Gastrointestinal disorders Dysgeusia 5.2
Eye disorders Vision blurred 5.0
Eye disorders Vision blurred 4.9
General disorders and administration site conditions Discomfort 4.4
Gastrointestinal disorders Dysgeusia 4.4
Eye disorders Vision blurred 2.8
General disorders and administration site conditions Discomfort
General disorders and administration site conditions Discomfort 2.5
Cardiac disorders Dyspnoea 2.0
Vascular disorders Hyperaemia 1.9
General disorders and administration site conditions Sensation of foreign body 1.8
Skin and subcutaneous tissue disorders Pruritus
Eye disorders Vision blurred
General disorders and administration site conditions Discomfort 1.5
Nervous system disorders Headache 1.3
Eye disorders Lacrimation increased 1.3
Eye disorders Vision blurred 1.3
Vascular disorders Hyperaemia 1.2
Eye disorders Keratitis 1.2
General disorders and administration site conditions Pain 1.2
Skin and subcutaneous tissue disorders Pruritus 1.2
Eye disorders Dry eye 1.1
Skin and subcutaneous tissue disorders Pruritus 1.1
Immune system disorders Asthma 1.0
General disorders and administration site conditions Pain 1.0
Infections and infestations Rhinitis 1.0
General disorders and administration site conditions Sensation of foreign body 1.0
Eye disorders Dry eye
Gastrointestinal disorders Dysgeusia
Nervous system disorders Headache
Vascular disorders Hyperaemia
General disorders and administration site conditions Pain
Skin and subcutaneous tissue disorders Pruritus 0.9
Immune system disorders Asthma 0.8
Nervous system disorders Headache 0.8
Vascular disorders Hyperaemia 0.8
General disorders and administration site conditions Sensation of foreign body 0.8
Eye disorders Keratitis 0.7
General disorders and administration site conditions Sensation of foreign body 0.6
Nervous system disorders Headache 0.5
Vascular disorders Hyperaemia 0.5
General disorders and administration site conditions Pain 0.5
Eye disorders Dry eye 0.4
General disorders and administration site conditions Pain 0.4
Cardiac disorders Dyspnoea 0.2
Eye disorders Lacrimation increased 0.2
Infections and infestations Rhinitis 0.2

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
25.42
General disorders and administration site conditions
13.13
Nervous system disorders
12.83
Respiratory, thoracic and mediastinal disorders
5.35
Gastrointestinal disorders
4.72
Cardiac disorders
4.43
Investigations
4.34
Injury, poisoning and procedural complications
4.27
Psychiatric disorders
4.14
Vascular disorders
4.05
Skin and subcutaneous tissue disorders
3.82
Musculoskeletal and connective tissue disorders
3.08
Immune system disorders
2.52

Cross References

Resources Reference
CAS NUMBER 138890-62-7
ChEBI 3176
ChEMBL CHEMBL220491
DrugBank DB01194
DrugCentral 396
EPA CompTox DTXSID6045531
FDA SRS 9451Z89515
Human Metabolome Database HMDB0015325
Guide to Pharmacology 6797
KEGG C07760
PDB BZ1
PharmGKB PA164744929
PubChem 68844
SureChEMBL SCHEMBL24636
ZINC ZINC000003953037
CONTENTS